Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐ TWiST ) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
Cancer Medicine · 2025
DOI: 10.1002/cam4.70780 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Ajibade Ashaye und 13 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Pyridazines, Imatinib Mesylate, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Imidazoles. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Centers Americas Inc., Cambridge, MA, USA, Takeda Pharmaceuticals U.S.A..
Abstract (Originalsprache)
Background
In the phase 3 ponatinib‐3001 trial (PhALLCON, NCT03589326), ponatinib demonstrated superior efficacy over imatinib with comparable safety in patients with newly diagnosed Philadelphia‐positive acute lymphoblastic leukemia (Ph+ ALL). This post hoc analysis evaluated the net benefits of ponatinib using a quality‐adjusted time without symptoms of disease or toxicity (Q‐TWiST) approach.
Methods
Overall survival (OS) time for patients from PhALLCON was partitioned into three health states: TOX (time with grade 3+ treatment‐emergent adverse events [TEAEs] before disease progression), TWiST (time without toxicity before progression), and REL (time from progression until death or end of follow‐up). Q‐TWiST was calculated as the sum of health utility‐weighted restricted mean durations of the three states. A relative Q‐TWiST gain of ≥ 10% was considered clinically important. Sensitivity analyses were conducted by varying TOX and REL utilities, follow‐up time, and the TOX definition (using grade 2+ TEAEs or patient‐perceived treatment tolerability assessed by the FACT‐GP5).
Results
Among all randomized patients (ponatinib n = 164, imatinib n = 81), restricted mean OS was similar between arms (1082.2 vs. 1024.8 days; p = 0.373). In the base‐case analysis, mean TWiST was 214.5 days longer with ponatinib versus imatinib (95% CI 70.3–358.7; p = 0.004), REL was shorter by 175.9 days (325.4–26.5; p = 0.021), and TOX was not significantly different between arms ( p = 0.228). The relative Q‐TWiST gain (10.98%) was clinically important. Sensitivity analyses consistently supported the robustness of the base‐case findings.
Conclusion
Ponatinib may prolong quality‐adjusted survival compared with imatinib, supporting the benefit–risk profile of ponatinib as a front‐line treatment for Ph+ ALL. Trial Registration NCT03589326
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Takeda Development Center Americas Inc., Cambridge, Massachusetts, USA.
- Evidera Inc., Bethesda, Maryland, USA.
- City of Hope National Medical Center, Duarte, California, USA.
- Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Instituto Do Câncer Do Estado de São Paulo, São Paulo, Brazil.
ORCID-Profile: Ajibade Ashaye, Ibrahim Aldoss, Pankit Vachhani, Jose-Maria Ribera
Förderung
- Takeda Development Centers Americas Inc., Cambridge, MA, USA
- Takeda Pharmaceuticals U.S.A.
Zitieren
APA
Ashaye, A., Shi, L., Aldoss, I., Montesinos, P., Vachhani, P., Rocha, V., Papayannidis, C., Leonard, J. T., Baer, M. R., Ribera, J. M., McCloskey, J., Wang, J., Rane, D., & Guo, S. (2025). Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐ TWiST ) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib. Cancer Medicine. https://doi.org/10.1002/cam4.70780
Vancouver
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha V, et al. Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐ TWiST ) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib. Cancer Medicine. 2025. doi:10.1002/cam4.70780
BibTeX
@article{Ashaye2025,
author = {Ashaye, Ajibade and Shi, Ling and Aldoss, Ibrahim and Montesinos, Pau and Vachhani, Pankit and Rocha, Vanderson and Papayannidis, Cristina and Leonard, Jessica T and Baer, Maria R and Ribera, Jose-Maria and McCloskey, James and Wang, Jianxiang and Rane, Deepali and Guo, Shien},
title = {Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐ TWiST ) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70780}
}
EUVIMED